Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pilulka Lekarny AS's EBIT per Share for the
six
months ended in Dec. 2025 was Kč0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was Kč0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 42.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Pilulka Lekarny AS's EBIT per Share or its related term are showing as below:
XPRA:PINK'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -262 Med: -109.95 Max: 42.1
Current: 42.1
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Pilulka Lekarny AS was 42.10% per year. The lowest was -262.00% per year. And the median was -109.95% per year.
XPRA:PINK's 3-Year EBIT Growth Rate is ranked better than 82.48% of 525
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs XPRA:PINK: 42.10
Pilulka Lekarny AS (XPRA:PINK) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Pilulka Lekarny AS EBIT per Share Related Terms
Pilulka Lekarny AS EBIT per Share Historical Data
* Premium members only.
The historical data trend for Pilulka Lekarny AS's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Kč0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS (XPRA:PINK) has a EBIT per Share of Kč0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pilulka Lekarny AS and its competitors. According to the industry distribution chart, Pilulka Lekarny AS ranks #92 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 17.5%.
Is Pilulka Lekarny AS's EBIT per Share too high?
Pilulka Lekarny AS's current EBIT per Share is Kč0.00. Based on the distribution chart, Pilulka Lekarny AS ranks #92 out of 525 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pilulka Lekarny AS has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pilulka Lekarny AS ranks #92 out of 525 companies for EBIT per Share. This places Pilulka Lekarny AS in the top 18% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pilulka Lekarny AS and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pilulka Lekarny AS's current EBIT per Share is Kč0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč112.54, compared to a current price of Kč106.50 — trading 5.4% below its estimated fair value. The current EBIT per Share is Kč0.00. Pilulka Lekarny AS's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current EBIT per Share is Kč0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be undervalued.
The current stock price of Kč106.50 is trading 5.4% below its estimated GF Value™ of Kč112.54.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
EBIT per Share: Kč0.00
GF Value™: Kč112.54 vs. price of Kč106.50 (5.4% below fair value)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
56GF Score
Get the complete analysis for XPRA:PINK
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
